Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Basel, December 11, 2021 — Novartis today announced new 48-week data from the Phase III ASCEMBL trial of Scemblix® (asciminib) demonstrating that the results observed in the primary analysis (24 weeks) vs. Bosulif®* (bosutinib) were maintained in longer-term follow up for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) previously treated with two or more tyrosine kinase inhibitors (TKIs)1-4.

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Basel, December 11, 2021 — Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular lymphoma (FL) based on a subgroup analysis from an approximately 17-month median follow-up of the pivotal Phase II ELARA study1. These results were presented in an oral session at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) (Abstract #131).

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Novartis is seeing strong interest from private equity investors as well as from other pharmaceuticals companies for the Sandoz generic drugs business it is considering selling, Chief Executive Vas Narasimhan said in a newspaper interview.

Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft

British American Tobacco

Cardinal Health

Imperial Brands PLC

Leggett & Platt

Realty Income Corp

Red Electrica Corp SA

Sanofi

Swiss Re AG

AT&T

Unilever

Exxon Mobil

Kiplinger "insights for investors" online, first-published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth compiled 7/1/21. 40 European “Dividend Aristocrats,” showed 10 years of stable or increasing dividends; 65 S&P 500 Aristocrats showed 25 years of increases for U.S. companies.

15 Best Dividends On Earth Priced To Buy In December

Basel, December 10, 2021 — Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in analyses from all three cohorts of BYLieve. BYLieve is an ongoing Phase II, open-label, 3-cohort non-comparative study evaluating Piqray with endocrine therapy including men and pre- and postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC) who have progressed on or after prior therapies, including CDK4/6 inhibitor plus endocrine therapy1-5. These data will be presented at the 2021 San Antonio Breast Cancer Symposium (SABCS) from December 7-10.

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Novartis's potential sale of its Sandoz generic drug business is attracting interest from possible buyers, Chief Executive Vas Narasimhan said in an interview to be published on Friday.

Novartis CEO says Sandoz attracting interest - paper

Novartis AG (NYSE: NVS) has reported the first interpretable results from year two (week 100) of the Phase 3 KESTREL study of Beovu (brolucizumab) 6 mg in patients with visual impairment due to diabetic macular edema (DME).  Results from year two of KESTREL were consistent with those seen at year one, including maintenance of best-corrected visual acuity and sustained reductions in central subfield thickness.

Novartis Reveals Two Year Results From Beovu Trial In Diabetic Macular Edema Patients

AbbVie

Amgen

VanEck Vectors Biotech ETF

Gilead Sciences

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends

Novartis AG (NYSE: NVS) shared new data from the MONALEESA Phase 3 program of Kisqali (ribociclib), the CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer and proven overall survival (OS) benefit across patient subgroups. The findings will be presented as a late-breaking oral presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).

Novartis' New Kisqali Data Shows Consistent Overall Survival Benefit Across Metastatic Breast Cancer Settings

Johnson & Johnson

Pfizer

Eighteen large U.S. and European drug companies will have more than $1.7 trillion in buying power by the end of 2022, according to SVB Leerink analyst Geoffrey Porges. That includes $500 billion in cash, which the companies can use for mergers and acquisitions, to pay down debt or reward shareholders via dividends or share buybacks, the Leerink analyst said.

J&J, Pfizer, Novartis Among Pharma Giants With Biggest War Chests

Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

Novartis (NVS) Highlights Growth Profile at its R&D Day

Merck

As 2021 winds down, investors may want to keep an eye on several drug companies that hope to get key approvals from the Food and Drug Administration before the year is out. Among the pharmas hoping to get their treatments green-lighted are Argenx SE ( ARGX , Financial), Calliditas Therapeutics AB ( CALT , Financial), Merck & Co. Inc. ( MRK , Financial) and Novartis ( NVS , Financial).

Merck, Novartis in Line for Key FDA Approvals This Month

Aurinia Pharmaceuticals

Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). The post AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today appeared first on InvestorPlace.

AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today

Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.

Novartis sees annual sales growth of 4% until 2026

Basel, December 2, 2021 — Novartis today holds an investor event to provide a comprehensive overview of the company's progress in advancing its industry-leading R&D engine.

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

AstraZeneca

Bristol-Myers

Horizon Pharma

Vertex Pharmaceuticals

Viatris

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. The post 7 Drug Stocks to Buy Now While They're Still on Sale appeared first on InvestorPlace.

7 Drug Stocks to Buy Now While They're Still on Sale

Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday.

Novartis chairman says all options open for Sandoz unit - report

Novartis' stock price does not seem to reflect its increasingly positive fundamentals.

Novartis: Management Should Repurchase The Discounted Stock

U.S. investors often focus on owning domestic companies, as this is the region of the world they are likely most familiar with. As such, this can limit the number of quality stocks available to them for purchase.

A Trio of International Health Care Stocks for Income

Roche Holding AG

Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said.

Roche shareholders approve deal to buy Novartis's stake

Many stocks are ridiculously expensive right now -- but not these three.

3 Pharma Stocks That Are Too Cheap to Ignore

CVS Health

Patterson Companies

Needless to say, 2021 has been a banner year for equities, with the S&P 500 up a stunning 25%.

Top Strategist Says Health Care Could Rule in 2022: 5 Dividend Winners

According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's (NYSE: NVS) generics outfit, Sandoz, for $21.6 billion. The price would make it the largest pharma deal of the year.

Novartis May Have Buyer(s) For Its Sandoz Unit - Report

BioNTech SE

Investment group EQT and members of the Struengmann family, who are investors in Biontech, are considering a joint bid for Swiss pharmaceutical group Novartis's generics division Sandoz, German newspaper Handelsblatt reported on Friday, citing unnamed sources.

EQT, Biontech investor family consider Sandoz bid - Handelsblatt

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation about where the Company will spend the money.  Another significant acquisition could be next.

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?

News for Novartis Stock (NVS)